Novo Nordisk Acquires Rights to Omeros’ MASP-3 Inhibitor Zaltenibart
Novo Nordisk secured exclusive global rights to develop and commercialize zaltenibart (OMS906), a clinical-stage MASP-3 inhibitor for rare blood and kidney disorders.
The agreement is valued at up to $2.1 billion, including $340 million in upfront and near-term milestone payments.
Tiered royalties on net sales provide long-term financial incentives for Omeros.